Aktuellt
SENASTE
Redeye believes there is a high likelihood Optomed will receive an approval by the FDA for the marketing of the autonomous AI for more than mild diabetic retinopathy - based on the presented clinical trial results with Aurora AEYE.
LÄS MER
